Wegovy Tablet Week by Week: What to Expect from Week 1 to Month 6

# Wegovy Tablet Week by Week: What to Expect from Week 1 to Month 6

Starting oral Wegovy is not like starting a course of antibiotics. There is no predictable moment when it “kicks in.” What there is instead is a gradual biological shift — a weekly accumulation of semaglutide in your system that slowly rewires the signals your brain receives about hunger, satiety, and food. This guide maps that shift, week by week and month by month, so you know what is normal, what to watch for, and what the evidence says about where you are likely to be at each stage.

> Wegovy tablets are a prescription-only medicine. Always consult a qualified healthcare professional before starting or changing treatment. The information in this guide is general and does not replace the advice of your prescribing clinician or the patient information leaflet supplied with your medication.

—

## Week 1 (1.5mg): the first dose lands

Day one feels unremarkable for most people. You take the tablet on an empty stomach, wait 30 minutes, and then carry on with your morning. Nothing dramatic happens in the first few hours. The tablet has been absorbed — or partly absorbed — and semaglutide is entering your bloodstream for the first time, but at levels too low to have a noticeable effect.

The experience typically changes somewhere between day two and day five. For a large proportion of people, nausea arrives during this window. It ranges from mild background queasiness to something that meaningfully disrupts the day. The nausea is caused by semaglutide’s effect on the GI tract and on the area of the brain that regulates nausea and appetite — it is the drug doing exactly what it is supposed to do, not a sign that something has gone wrong. Energy levels often dip in week one as the body adjusts. Some people feel slightly flat or fatigued in the early days.

Appetite suppression may be present but is usually subtle. You might notice a slight reduction in interest in food, or that a smaller portion than usual leaves you satisfied. Do not expect a dramatic change yet — you are at 1.5mg, which is a very low dose by design.

**Weight in week 1:** Any loss on the scale at this stage is likely to be water weight and is not representative of what the drug will do long-term. For most people, week-one weight loss is zero to 2kg. Some see no change at all. This is completely normal.

—

## Weeks 2–4 (1.5mg continues): the hardest stretch

Most people find weeks two and three the most challenging part of the entire treatment journey. This is when side effects typically peak. Nausea, if it has arrived, is usually at its worst around weeks two and three. Some people also experience constipation, fatigue, or a reduced tolerance for fatty or heavily seasoned food.

The critical thing to understand about this period is that it is temporary. The side effects at this phase are not a forecast of how you will feel for the rest of treatment — they are a start-up response that the body largely adapts to. Clinical data from the OASIS trials and from patient experience with injectable semaglutide consistently shows that GI side effects diminish significantly after the initial dose stabilisation period.

By weeks three and four, appetite suppression becomes more noticeable. Meals start to feel like less of a focus. Cravings — particularly for processed, high-calorie foods — begin to reduce. Many people first notice the effect not because they feel dramatically different, but because they realise they forgot to eat lunch, or that their usual afternoon biscuit habit has simply fallen away.

**Weight at end of month 1:** Total weight loss by the end of week four varies considerably. A typical range based on clinical trial data and patient experience is 1–4kg. People who experience significant nausea may lose more due to reduced intake; people who have milder side effects may lose less. Neither outcome is a reliable predictor of long-term results — those come with dose escalation.

—

## Weeks 5–8 (transitioning to 4mg): appetite suppression becomes reliable

Around week five, your prescriber will typically move your dose from 1.5mg to 4mg. This transition may bring a brief return of mild side effects — a recurrence of nausea for a few days, or some digestive disruption — but for most people this second-phase adjustment is considerably milder than the first.

If you are remaining at 1.5mg at this point (some prescribers extend the starting dose period for patients who need more time to tolerate it), side effects should have settled considerably by week six or seven. Energy levels typically return. Many people feel better at this point than they did before starting treatment — not because of dramatic weight loss yet, but because the drug is reducing appetite without the side effect burden of the first weeks.

At 4mg, the appetite suppression becomes more consistent and more pronounced. Food noise — the constant mental chatter about what to eat, when to eat, and craving for specific foods — quietens for many people. This is one of the most commonly reported qualitative experiences of GLP-1 treatment and for many patients is the most meaningful early change, even before significant weight comes off.

**Weight at end of weeks 5–8:** Cumulative weight loss at this stage is typically in the range of 3–6kg for people responding well. Clothes may start to fit differently. Progress on the scale is happening, though it is rarely dramatic week-to-week at this stage.

—

## Months 3–4 (4mg, possibly 9mg): the drug begins to deliver

By month three, you are likely experiencing the consistent effects of therapeutic semaglutide levels as your dose has moved to 4mg and possibly 9mg. This is the period most people describe as when the treatment “clicked.”

Appetite suppression at this phase is no longer just a reduction in hunger — it is a different relationship with food. Portions that would once have been normal now feel like too much. The urgency of eating, the preoccupation with meals and snacks, reduces significantly. The effort required to eat less is lower because the drive to eat more has been pharmacologically reduced.

The 9mg dose, introduced around week nine to thirteen depending on your prescriber’s protocol, brings another step up in efficacy. Some patients experience a brief recurrence of mild GI effects as the dose escalates. Most find this phase produces the most visible progress.

**Weight at months 3–4:** The OASIS 4 trial data shows average weight loss of around 5–8% of starting body weight by this point in treatment. For a person starting at 100kg, that is 5–8kg. For someone starting at 120kg, that is 6–10kg. These are averages — there is real variance in individual response. Importantly, people who are not yet showing significant loss at this stage are not necessarily non-responders: some people show delayed but substantial response when the full dose is reached.

—

## Months 5–6 (approaching 25mg maintenance): the most significant loss phase

By months five and six, many patients have reached or are close to the 25mg maintenance dose — the point at which semaglutide is at full therapeutic efficacy as approved in the OASIS programme. This is typically the most productive phase of treatment for weight loss.

Appetite suppression at 25mg is at its maximum. Most people at this stage are eating noticeably less than before treatment, not through willpower but because the biological drive to eat has been reduced. The drug is also affecting gastric emptying — food stays in the stomach longer, which contributes to the sense of fullness after smaller meals.

**Weight at months 5–6:** Total weight loss at six months varies substantially across individuals, but the OASIS trial data suggests a range of 8–12% of starting body weight for most participants, with some achieving more. At 100kg starting weight, that is 8–12kg. The headline OASIS 4 result of 16.6% weight loss was achieved at 64 weeks (approximately 15 months) — it is not a six-month figure.

For some people, a plateau appears at this stage. The scale may stall for two to four weeks despite continued treatment adherence. This is normal. The body responds to calorie deficits by downregulating metabolism to some degree. A plateau is not evidence that the drug has stopped working — it is a temporary adaptation. The plateau typically breaks when metabolic adaptation stabilises.

—

## What affects your results

Several factors meaningfully influence how you respond week by week. Starting weight matters: people with higher BMIs tend to lose a higher absolute number of kilograms in the early months because there is more to lose and because the metabolic impact of the drug is proportionally larger. Adherence to the fasting protocol is non-negotiable — skipping the 30-minute window even occasionally substantially reduces absorption and blunts results.

Diet quality matters, though the drug does not require a specific diet. Reducing processed food, increasing protein intake, and maintaining adequate fibre all support better outcomes. Exercise, particularly resistance training, helps preserve muscle mass during weight loss — important because weight loss without exercise tends to lose lean mass alongside fat. Alcohol intake reduces the effectiveness of GLP-1 treatment and adds empty calories; many patients find their tolerance for alcohol reduces significantly while on semaglutide, which is pharmacologically expected.

Sleep quality has a significant but underappreciated effect on weight loss outcomes. Poor sleep disrupts the hormonal environment that GLP-1 drugs work within. If sleep quality is poor, addressing it is likely to improve treatment response.

—

## The plateau: what to do when the scale stalls

Hitting a weight loss plateau at any point in treatment is common and does not mean you should stop. The body’s homeostatic response to sustained calorie deficit involves slowing metabolism, reducing non-exercise activity, and conserving energy in other ways. This adaptive thermogenesis is a normal biological response and tends to stabilise after several weeks.

Strategies that support breaking a plateau: reviewing diet quality rather than reducing calories further (eating enough protein is more important than eating very little); adding or increasing resistance training; ensuring sleep quality is good; and speaking with your prescriber if the plateau extends beyond 12 weeks at the maintenance dose.

—

## Frequently asked questions

### What if I don’t feel nauseous — does that mean the tablet isn’t working?

Not at all. Nausea is the most common side effect but it is not universal. A minority of patients on oral semaglutide experience little or no nausea, particularly at the starting dose. The absence of nausea does not indicate inefficacy. The drug’s mechanism of action does not depend on causing GI distress — nausea is a side effect, not an intended effect. If you have no nausea but are experiencing reduced appetite or any weight loss, the medication is working.

### Is losing 1kg per week realistic on oral Wegovy?

At the maintenance dose of 25mg, approximately 1kg per week is achievable for some people in the months of most active weight loss. However, this rate is not sustained throughout treatment and is not typical across all patients. Average weight loss in the OASIS trials over 64 weeks was 16.6% — roughly 0.25kg per week averaged across the full treatment period. Some weeks will be faster, some will be slower, and there will be plateaus.

### I’ve hit a plateau after three months — what should I do?

Three months into treatment, many patients are still on lower doses rather than the full 25mg maintenance dose. A plateau at this stage may resolve naturally as the dose escalates. If you are already at the maintenance dose, review diet quality, particularly protein intake and alcohol consumption. Ensure you are taking the tablet correctly with the full fasting protocol. If the plateau extends beyond 8–12 weeks at the maintenance dose despite full adherence, speak to your prescriber.

### What does week 1 nausea feel like on the Wegovy tablet?

Most people describe early Wegovy tablet nausea as a persistent background queasiness rather than the acute nausea of illness or food poisoning. It is typically worse after eating — particularly after eating too much or eating fatty or rich food — and may be accompanied by a general lack of interest in food. It is usually manageable rather than debilitating, though a minority of patients find it severe enough to contact their prescriber. Cold bland foods, ginger, and small portions help most people through this initial phase.

### When should I contact my prescriber during the first weeks?

Contact your prescriber if nausea is severe enough that you cannot keep fluids down, if you experience severe abdominal pain (which could indicate pancreatitis and requires urgent assessment), if you develop symptoms of pancreatitis or gallbladder problems, or if you are concerned about your progress at any point. Mild to moderate GI symptoms in the first four weeks are expected and do not usually require clinical intervention.

—

*This article is for informational purposes only and does not constitute medical advice. Wegovy tablets (oral semaglutide) are a prescription-only medicine available in the UK. Always consult a registered UK healthcare professional before starting any weight management treatment, and follow the patient information leaflet supplied with your medication. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk.*